Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07368660 · ClinicalTrials.gov registry record · NA
InPART RX - Epicenters
A NA study of Hospital Infection and Standardized Antibiotic Prescribing Ratio (SAR), sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 169
- Enrollment target
- 4
- Study locations
NCT07368660 is a NA study of Hospital Infection and Standardized Antibiotic Prescribing Ratio (SAR) that has completed, run by Emory University. The registered enrollment target is 169 participants. The trial reports 4 study locations across 1 state.
The verdict
NCT07368660, a NA study of Hospital Infection and Standardized Antibiotic Prescribing Ratio (SAR), has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 169 participants
- Enrollment target
- 4
- Study locations
Study Summary
InPART Rx is a collaborative research study to measure the impact of a planned quality improvement initiative to reduce unnecessary antibiotic prescribing by the Hospital Medicine Service through a process of receiving peer-comparison summary prescribing data bimonthly. The initiative is a collaboration between EHC Pharmacy, the School of Medicine (SOM) Division of Infectious Diseases, and the SOM Hospital Medicine Service. Roughly one-third of antibiotics prescribed in the hospital setting are for the wrong dose, wrong drug, or wrong duration, resulting in considerable unnecessary antibiotic exposure among the inpatient population. Such use increases patient risk for adverse events such as infectious diarrhea or antibiotic-resistant infections. Inpatients cared for by Hospital Medicine providers are a growing proportion of all patients, and developing efficient techniques to reduce unnecessary antibiotic prescribing by these providers would benefit this growing population of patients. The research team aims to measure the impact of implementing a process to provide peer comparisons of antibiotic prescribing among Hospitalists at four Emory Healthcare (EHC) hospitals back to these providers in an effort to minimize unnecessary antibiotic prescribing. All 147 current Hospital Medicine Service providers will participate as part of the Division's quality improvement effort, receiving no compensation. Only summary patient encounter information without private health insurance (PHI) will be presented back to the providers; investigators will track changes in summary prescribing metrics and summary patient outcomes every month. If such an automated peer-comparison feedback process is effective in safely reducing unnecessary antibiotic prescriptions in EHC, similar processes may be adapted to other inpatient provider groups or serve as a model for other healthcare systems. The goal of this quality improvement (QI) work is to use traditional QI methods of peer-comparison
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER Messaging Hospitalists
Study Locations (4)
Georgia
- Emory Saint Joseph's Hospital - Atlanta
- Emory University Hospital Midtown (EUHM) - Atlanta
- Emory University Hospital (EUH) - Atlanta
- Emory Johns Creek Hospital - Johns Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07368660
The ClinicalTrials.gov registry entry for NCT07368660 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hospital Infection appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT07368660 reports 4 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT07368660 about?
NCT07368660 is a clinical study titled "InPART RX - Epicenters". InPART Rx is a collaborative research study to measure the impact of a planned quality improvement initiative to reduce unnecessary antibiotic prescribing by the Hospital Medicine Service through a process of receiving peer-comparison summary prescribing data bimonthly. The initiative is a collabora...
What is the current status of trial NCT07368660?
This trial is currently completed. It is a NA study. The enrollment target is 169 participants. The study started on 2023-01-01. Estimated completion is 2024-12-31.
What conditions does trial NCT07368660 study?
This clinical trial studies the following conditions: Hospital Infection, Standardized Antibiotic Prescribing Ratio (SAR).
What interventions are being tested in trial NCT07368660?
The interventions under investigation include: Usual Care (OTHER), Messaging Hospitalists (OTHER).
Who is sponsoring clinical trial NCT07368660?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07368660 being conducted?
This trial has 4 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Hospital Infection
All registered trials for this condition
Standardized Antibiotic Prescribing Ratio (SAR)
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.